DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY Russian patent published in 2022 - IPC A61K35/12 A61K35/28 A61P43/00 

FIELD: molecular biology; cellular biology; medicine; pharmacology.

SUBSTANCE: invention relates to the field of molecular and cellular biology, medicine and pharmacology, in particular to a drug for the treatment of tissue fibrosis, a method for its preparation and a method for the treatment of fibrosis caused by tissue damage using the specified drug. The drug contains a fraction of extracellular vesicles in the secretome of mesenchymal stromal cells (hereinafter – MSC) or an isolated fraction of extracellular vesicles isolated from the secretome of MSC having surface markers HSP70, CD9, CD81 and CD63, as well as a diameter size from 20 to 420 nm, in the amount of 1-3*10^10 particles per ml. Extracellular vesicles carry special microRNA in their composition. To implement the method for obtaining the specified drug, human MSC are first cultured to 90% of confluent or monolayer in a medium that supports the growth of undifferentiated human mesenchymal cells. Then, cells are washed with a buffer solution, and MSC are conditioned in a serum-free and animal-free growth medium that supports cell viability of at least 70% and that is suitable for therapeutic use, for 2-7 days. After that, the cultivation medium containing secretion products of human MSC is selected, cell residues are removed from it, and it is purified from low-molecular components, followed by concentration using ultrafiltration. Next, the specified medium is evaluated for the content of the fraction of extracellular vesicles with surface markers, the size and number of particles per ml are determined, as well as the presence of the specified microRNA in their composition is evaluated. At the same time, 10 kDa filters are used to obtain a fraction of extracellular vesicles in human MSC secretome, and 1000 kDa filters are used to obtain an isolated fraction of extracellular vesicles isolated from MSC secretome, with an acceptable error value of no more than 5%.

EFFECT: present invention makes it possible to expand the arsenal of means that effectively suppress tissue fibrosis or prevent the development of tissue fibrosis.

28 cl, 16 dwg, 4 tbl, 10 ex